Literature DB >> 9552229

The central role of chemokines (chemotactic cytokines) in the immunopathogenesis of ulcerative colitis and Crohn's disease.

R P MacDermott1, I R Sanderson, H C Reinecker.   

Abstract

The final composition of leukocytes present in a site of inflammation in response to chemokine stimulation and activation may depend on both the nature of the secreted chemokines as well as the relative expression of the multitude of specific chemokine cell surface receptors on many different cell types. Because related receptors with different affinities and cross-reactive binding capabilities are present on each type of leukocyte, relative differences in receptor distribution and receptor affinity for specific chemokines may significantly influence which cells are ultimately attracted to and activated by each individual chemokine. Production of IL-8, MCP-1, and ENA-78 by endothelial cells, LPMNC, and epithelial cells in IBD could establish a chemotactic gradient capable of influencing the increased migration of monocytes/macrophages, granulocytes, and lymphocytes from the blood stream through the endothelium into both the mucosa and submucosa during chronic IBD. The ability of chemokines to induce chemotaxis, leukocyte activation, granule exocytosis, increased production of metalloenzymes, and up-regulation of respiratory burst activity indicates that there may be a variety of different mechanisms by which chemokines could markedly increase chronic inflammation and chronic intestinal tissue destruction in IBD.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9552229     DOI: 10.1097/00054725-199802000-00009

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  33 in total

1.  Enhanced production of IL-8 in chronic but not in early ileal lesions of Crohn's disease (CD).

Authors:  E Brandt; J F Colombel; N Ectors; L Gambiez; D Emilie; K Geboes; M Capron; P Desreumaux
Journal:  Clin Exp Immunol       Date:  2000-11       Impact factor: 4.330

Review 2.  Molecular machinations: chemokine signals in host-pathogen interactions.

Authors:  S W Chensue
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

3.  Inflammatory Bowel Disease: Future Therapies.

Authors:  Sander J.H. Van Deventer
Journal:  Curr Treat Options Gastroenterol       Date:  2002-06

4.  The N-terminal fragment of chromogranin A, vasostatin-1 protects mice from acute or chronic colitis upon oral administration.

Authors:  Cristiano Rumio; Giuseppina F Dusio; Barbara Colombo; Anna Gasparri; Diego Cardani; Fabrizio Marcucci; Angelo Corti
Journal:  Dig Dis Sci       Date:  2012-01-26       Impact factor: 3.199

Review 5.  Chemokines in inflammatory bowel disease.

Authors:  S Danese; A Gasbarrini
Journal:  J Clin Pathol       Date:  2005-10       Impact factor: 3.411

6.  Rho activation regulates CXCL12 chemokine stimulated actin rearrangement and restitution in model intestinal epithelia.

Authors:  Rebecca A Moyer; Michael K Wendt; Priscilla A Johanesen; Jerrold R Turner; Michael B Dwinell
Journal:  Lab Invest       Date:  2007-06-18       Impact factor: 5.662

Review 7.  The possible role of isolated lymphoid follicles in colonic mucosal repair.

Authors:  Ferenc Sipos; Györgyi Muzes; Orsolya Galamb; Sándor Spisák; Tibor Krenács; Kinga Tóth; Zsolt Tulassay; Béla Molnár
Journal:  Pathol Oncol Res       Date:  2009-06-26       Impact factor: 3.201

8.  Expression Profiling of Inflammatory and Immunological Genes in Collagenous Colitis.

Authors:  Qingqing Liu; Noam Harpaz
Journal:  J Crohns Colitis       Date:  2019-05-27       Impact factor: 9.071

9.  CCR6 regulation of the actin cytoskeleton orchestrates human beta defensin-2- and CCL20-mediated restitution of colonic epithelial cells.

Authors:  Rebecca A Vongsa; Noah P Zimmerman; Michael B Dwinell
Journal:  J Biol Chem       Date:  2009-02-20       Impact factor: 5.157

Review 10.  Chemokines and chemokine receptors in mucosal homeostasis at the intestinal epithelial barrier in inflammatory bowel disease.

Authors:  Noah P Zimmerman; Rebecca A Vongsa; Michael K Wendt; Michael B Dwinell
Journal:  Inflamm Bowel Dis       Date:  2008-07       Impact factor: 5.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.